Results 111 to 120 of about 5,747 (197)

Therapeutic potential of immunoproteasome inhibition in Duchenne muscular dystrophy

, 2016
DMD arose from mutation of dystrophin protein determining loss of muscle force and inflammation . Emerging data from several laboratories demonstrated that immunoproteasomes exert a plethora of functions, in addition to the best-known immunological one ...
R. Rigoni, F. Colleoni, F. Napolitano, R. Maiavacca, Y. Torrente, B. Cassani, A. Villa, L. Cassinelli, A. Farini, C. Sitzia   +9 more
core   +1 more source

Sweet Syndrome Beyond the Neutrophil. [PDF]

Exp Dermatol
Nakamizo S.
europepmc   +1 more source

Pan-cancer analysis identifies immunoproteasome as the predominant survival-associated component of antigen processing machinery. [PDF]

Transl Oncol
Lai JI, Liu CY, Tsai YF, Huang CC, Tseng LM, Chao TC.   +5 more
europepmc   +1 more source

From probe to prodrug: immunoproteasome activity as a trigger for disease-selective therapeutics. [PDF]

Signal Transduct Target Ther
Loy CA, Gu Y, Kim SC, Mohagheghi MV, Trask NB, Suarez-Pizarro M, Wagar LE, Benavente CA, Trader DJ.   +8 more
europepmc   +1 more source

Differential regulation of SOCS signalling and immunoproteasome pathways by JAK inhibitors and TNF inhibitors in rheumatoid arthritis. [PDF]

Arthritis Res Ther
Ghannam K, My LN, Behrendt C, Brunner-Weinzierl M, Lux A, Bertrand J, Wille A, Gläß M, Heinemann-Dammann S, Borucki K, Feist E.   +10 more
europepmc   +1 more source

Sex-specific remodeling of proteasome complexes in lymph nodes of aged BTBR mice. [PDF]

Front Aging
Monittola F, Bruschi M, Masini S, Losito DP, Magnani M, Rossi L, Fraternale A, Crinelli R.   +7 more
europepmc   +1 more source

PA200 modulates immunoproteasome structure and activity. [PDF]

Nat Commun
Živković D, Bosc-Rosati A, Dafun AS, Mourtada F, Grygier P, Yazgili AS, Jansma M, Rawski M, Czarna A, Bohn S, Zak KM, Santos Dias Mourão A, Reiling N, Zemke L, Guo K, Behr J, Burlet-Schiltz O, Popowicz GM, Marcoux J, Meiners S, Bousquet MP.   +20 more
europepmc   +1 more source

Effect of the Proteasome Inhibitor, Bortezomib, on Histone Modifications in Human Leukemic Cell Lines. [PDF]

Int J Mol Sci
Sattarifard H, Oyeyode M, Prajapati D, Duaqui A, Kaur G, Muker I, Luo W, Lakowski TM, Davie JR.   +8 more
europepmc   +1 more source

Pharmacokinetics, Target Engagement of an Immunoproteasome Subunit Low-Molecular-Mass Polypeptide‑2 (LMP2) Inhibitor AR-01, and Its Anti-Alzheimer's Effects in Rodents. [PDF]

ACS Pharmacol Transl Sci
Thapa Magar TB, Kim M, Kim Y, Choi EY, Choi YK, Kim DE, Kim KB, Park JE.   +7 more
europepmc   +1 more source

Dominant-negative PSMB10 disrupts immunoproteasome assembly and leads to transient T lymphopenia. [PDF]

J Hum Immun
Ghosh S, Wang Y, Schultheiss C, Borkhardt A, Dafun AS, Knipp L, Marwitz S, Ehl S, Soulard C, Haddad E, Dey D, Evans G, Golwala ZM, Bennstein SB, Laws HJ, Rohlfs M, Magg T, Binder M, Kreins AY, Bousquet MP, Marcoux J, Klein C, Conn GL, Meiners S, Hauck F.   +24 more
europepmc   +1 more source